Context Therapeutics Inc. (NASDAQ: CNTX)
$1.0200
N/A ( -3.77% ) 15.0M
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of innovative therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 ("CLDN6") x anti-CD3 bispecific antibody ("bsAb") that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
Market Data
Open
$1.0200
Previous close
$1.0200
Volume
15.0M
Market cap
$76.50M
Day range
$0.9380 - $1.2940
52 week range
$0.8900 - $2.7500
SEC Filings
Form Type | Description | Pages | Date |
---|---|---|---|
10-q | Quarterly Reports | 59 | Aug 07, 2024 |
3 | Insider transactions | 2 | Aug 01, 2024 |
4 | Insider transactions | 1 | Aug 01, 2024 |
def | Proxies and info statements | 4 | Jul 24, 2024 |
pre | Proxies and info statements | 4 | Jul 12, 2024 |
8-k | 8K-related | 46 | Jul 10, 2024 |
4 | Insider transactions | 1 | Jun 14, 2024 |
4 | Insider transactions | 1 | Jun 14, 2024 |
4 | Insider transactions | 1 | Jun 14, 2024 |
4 | Insider transactions | 1 | Jun 14, 2024 |